Ziprasidone Mesylate

Treats schizophrenia. Sold as Geodon. Every FDA application for this active ingredient: 1 branded and 3 generic.

As of Nov 15, 2026, FDA lists 4 applications for Ziprasidone Mesylate (sold as Geodon), first approved Jun 21, 2002, with 0 new uses approved and 0 published complete response letters.

First approved: Jun 21, 2002
Applications: 4
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $406K

Medicare Spending

CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name

Product	Part	Spending, 2025	Change	Beneficiaries
Ziprasidone Mesylate	Part D	$406K	-17%	1,162

What Pharmacies Pay

Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change

ZIPRASIDONE 20 MG/ML VIAL: $21.81 per unitGeneric · +17% in a year
ZIPRASIDONE HCL 20 MG CAPSULE: $0.218 per unitGeneric · -29% in a year
ZIPRASIDONE HCL 40 MG CAPSULE: $0.265 per unitGeneric · +3% in a year
ZIPRASIDONE HCL 60 MG CAPSULE: $0.332 per unitGeneric · +3% in a year
ZIPRASIDONE HCL 80 MG CAPSULE: $0.272 per unitGeneric · -23% in a year
GEODON 80 MG CAPSULE: $31.11 per unitBrand · +5% in a year

Clinical Trials

3 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all


Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.Apathy, Schizophrenia · Louisiana State University Health Sciences Center Shreveport	Phase 3	Recruiting	Jul 1, 2024
Maternal And Infant Antipsychotic StudyAntipsychotics, Pregnancy · Icahn School of Medicine at Mount Sinai	—	Recruiting	Sep 22, 2023
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For SchizophreniaSchizophrenia · University of Arizona	Phase 1	Active, not recruiting	Dec 19, 2018

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history


Jun 21, 2002	GeodonNDA 20919 · New dosage form	Viatris	26	Marketed
Dec 26, 2019	Ziprasidone MesylateANDA 211908	Gland	4	Marketed
Sep 15, 2022	Ziprasidone MesylateANDA 216091	Msn	0	Marketed
Sep 3, 2025	Ziprasidone MesylateANDA 217595	Steriscience	0	Marketed

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA